Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HCN1 | O60741 | 1/20 | 0.30 |
| ▸ | HCN3 | Q9P1Z3 | 1/20 | 0.30 |
| ▸ | HCN2 | Q9UL51 | 1/20 | 0.30 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71979 | 0.87 | SOS1 (0.33) | SOS1SOS2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31094814 | 0.85 | SOS1 (0.32) | SOS1SOS2ALDH1A1 | |
| Azepane SCHEMBL15201352 | 0.82 | ALDH1A1 (0.39) | OPRM1OPRL1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL25003069 | 0.81 | — | — | |
| SCHEMBL16834077 | 0.81 | CCR5 (0.35) | SOS1SOS2OPRM1OPRL1OPRD1 | |
| SCHEMBL24176431 | 0.80 | SOS1 (0.44) | SOS1SOS2 | |
| SCHEMBL6496554 | 0.79 | GRIN1 (0.37) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL633802 | 0.79 | GRIN1 (0.37) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL1515302 | 0.79 | GRIN1 (0.37) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL13300994 | 0.79 | GRIN1 (0.37) | OPRM1OPRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066259-B | Synthesis and use of MSE framework type molecular sieves | EXXONMOBIL RES & ENG CO | 2014-01-15 | — | — | CN | claimed |
| CN-102066259-A | Synthesis and use of MSE framework type molecular sieves | EXXONMOBIL RES & ENG CO | 2011-05-18 | — | — | CN | claimed |
| WO-2017045750-A1 | COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017045750-A1 | COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| CN-102066259-B | Synthesis and use of MSE framework type molecular sieves | EXXONMOBIL RES & ENG CO | 2014-01-15 | — | — | CN | disclosed |
| CN-102066259-A | Synthesis and use of MSE framework type molecular sieves | EXXONMOBIL RES & ENG CO | 2011-05-18 | — | — | CN | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| EP-1888530-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006120478-A2 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | TACR2, TACR3, NPY2R | SOS1 4733/4885SOS2 4443/4885OPRM1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.